How Insurance Payers Allying With Providers Can Lead to Efficient Health Outcomes

Improving healthcare Insurance payers greatly influence outcomes and patient experiences and the subject has become a hot-button issue, especially as the costs of healthcare continues to escalate. In an industry that accounted for nearly 18 percent of the U.S. GDP in 2021, the insurance payers’ role in improving healthcare access, experience, and outcomes is crucial. The timely discourse surrounding their impact, responsibilities, and potential for bridging gaps in the healthcare system is more significant than ever.

What is the role of insurance payers in improving healthcare? How are insurance companies responding to the call for more accessible and effective healthcare? How can they collaborate with providers, patients, and technology innovators to deliver better outcomes?

These critical questions were answered in an episode of “Highway to Health,” hosted by healthcare advocate and podcast host, David Kemp who interviewed Dr. Samrat Ambewadikar, MD, Regional Vice President and Medical Director of National Accounts at Anthem, one of the largest insurance companies in the country. The discussion delved into the payer’s perspective of healthcare, their efforts to be an ally to all stakeholders, and their vision for the future of health.

The main points of conversation between Kemp and Ambewadikar included:

  • The responsibility and role of insurance payers in improving healthcare access and outcomes
  • The potential for digital health solutions and software innovations in aiding providers
  • The importance of self-care, physical activity, and healthy lifestyle habits among healthcare executives

Dr. Ambewadikar is a respected figure in the healthcare industry with years of experience in strategic roles at Anthem, one of the largest health insurance providers in the United States. He is an advocate for physical fitness, nutrition, and self-care, leveraging these principles in his personal life and professional practice. His insights stem from a blend of medical expertise and executive leadership in the payer sector of healthcare.

Recent Episodes

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…